Business
INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca
About this update from Inmune Bio Inc.
[{"type":"text","content":"RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease has been invited to discuss drug development strategies in aging and rejuvenation at the 5th World Aging and Rejuvenation Conference in Frankfurt, Germany on July 17, 2023. Modern medicine has extended the average life span to more than 75 years old in the US.. An unintended consequence of this extended life span is a decline in overall health in the latter years of life. Health span, which refers to the period of life characterized by good health, is currently at odds with life span due to the prevalence of chronic diseases of aging. Chronic diseases of aging affect virtually every organ system, including the heart, brain, eyes, ears, bones, and skeletal muscles. Unfortunately, they contribute to a diminished health span, resulting in shortened life spans, increased elder care costs, and reduced quality of life. Many of these chronic diseases of aging are the result of chronic inflammation, leading the National Institute of Health to term it \"inflammaging.\" Inflammaging is characterized by a persistent, low-grade inflammation that develops with advancing age, independent of apparent infections, and potentially exacerbates other age-related conditions. Cognitive aging is one of the most prevalent chronic diseases associated with advancing age. Almost all adults have a gradual decline in cognitive function that becomes meaningful in the mid 50s then accelerates after age 65. . It is important to differentiate cognitive aging from Alzheimer’s disease (AD). AD appears around the eighth decade of life, exhibits more pronounced cognitive dysfunction and is characterized by amyloid plaques. “Cognitive aging is a well-defined disease that has not been the subject of extensive clinical study or intervention,” said CJ Barnum, VP CNS Development at INmune Bio. “We believe cognitive aging is driven by neuroinflammation. INmune Bio has developed biomarkers specifically designed to measure neuroinflammation in Early AD patients, that are well-suited for s...